[1]
|
Jemal, A., Thomas, A., Murray, T., et al. (2022) Cancer Statistics, 2022. CA: A Cancer Journal for Clinicians, 52, 23-47. https://doi.org/10.3322/canjclin.52.1.23
|
[2]
|
Zhi, X.Y., Zou, X.N., Hu, M., et al. (2015) Increased Lung Cancer Mortality Rates in the Chinese Population from 1973-1975 to 2004-2005: An Adverse Health Effect from Exposure to Smoking. Cancer, 121, 3107-3112.
https://doi.org/10.1002/cncr.29603
|
[3]
|
Bl, A., Xs, B., Dy, A., et al. (2018) Anlotinib Inhibits Angiogenesis via Suppressing the Activation of VEGFR2, PDGFRβ and FGFR1. Gene, 654, 77-86. https://doi.org/10.1016/j.gene.2018.02.026
|
[4]
|
Shen, G., Zheng, F., Ren, D., et al. (2018) Anlotinib: A Novel Multi-Targeting Tyrosine Kinase Inhibitor in Clinical Development. Journal of Hematology & Oncology, 11, Article No. 120. https://doi.org/10.1186/s13045-018-0664-7
|
[5]
|
Han, B., Li, K., Wang, Q., et al. (2018) Effect of Anlotinib as a Third-Line Orfurther Treatment on Overall Survival of Patients with Advanced Nonsmall Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncology, 4, 1569-1575. https://doi.org/10.1001/jamaoncol.2018.3039
|
[6]
|
Cheng, Y., Wang, Q., Li, K., et al. (2021) Anlotinib vs Placebo as Third- or Further-Line Treatment for Patients with Small Cell Lung Cancer: A Randomised, Double-Blind, Place-bo-Controlled Phase 2 Study. British Journal of Cancer, 125, 366-371. https://doi.org/10.1038/s41416-021-01356-3
|
[7]
|
Li, D., Chi, Y., Chen, X., et al. (2021) Anlotinib in Locally Ad-vanced or Meta-Static Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase ⅡB Trial. Clinical Cancer Research, 27, 3567-3575.
https://doi.org/10.1158/1078-0432.CCR-20-2950
|
[8]
|
Chi, Y., Fang, Z., Hong, X., et al. (2018) Safety and Effi-cacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma. Clinical Cancer Research, 24, 5233-5238.
https://doi.org/10.1158/1078-0432.CCR-17-3766
|
[9]
|
Sun, Y., Zhou, A., Zhang, W., et al. (2021) Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma: An Open-Label Phase II Study (ALTER-0802 Study). Hepatology International, 15, 621-629.
https://doi.org/10.1007/s12072-021-10171-0
|
[10]
|
Ma, J., Song, Y., Shou, J., et al. (2020) Anlotinib for Patients with Metastatic Renal Cell Carcinoma Previously Treated with One Vascular Endothelial Growth Factor Recep-tor-Tyrosine Kinase Inhibitor: A Phase 2 Trial. Frontiers in Oncology, 10, 664. https://doi.org/10.3389/fonc.2020.00664
|
[11]
|
Huang, J., Xiao, J., Fang, W., et al. (2021) Anlotinib for Previously Treated Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Double-Blind Randomized Phase 2 Trial. Cancer Medicine, 10, 1681-1689.
https://doi.org/10.1002/cam4.3771
|
[12]
|
Chi, Y., Shu, Y., Ba, Y., et al. (2021) Anlotinib Monotherapy for Refrac-tory Metastatic Colorectal Cancer: A Double-Blinded, Placebo Controlled, Randomized Phase III Trial (ALTER0703). The Oncologist, 26, e1693-e1703.
https://doi.org/10.1002/onco.13857
|
[13]
|
Majidpoor, J. and Mortezaee, K. (2021) Angiogenesis as a Hallmark of Solid Tumors. Clinical Perspectives Cellular Oncology, 44, 715-737. https://doi.org/10.1007/s13402-021-00602-3
|
[14]
|
Folkman, J. (1995) Angiogenesis in Cancer, Vascular, Rheuma-toid and Other Disease. Nature Medicine, 1, 27-31.
https://doi.org/10.1038/nm0195-27
|
[15]
|
Nishida, N., Yano, H., Nishida, T., Kamura, T. and Kojiro, M. (2006) An-giogenesis in Cancer. Vascular Health and Risk Management, 2, 213-219. https://doi.org/10.2147/vhrm.2006.2.3.213
|
[16]
|
Cardoso, H.J., Figueira, M.I., Correia, S., et al. (2014) The SCF/c-KIT System in the Male: Survival Strategies in Fertility and Cancer. Molecular Reproduction and Development, 81, 1064-1079. https://doi.org/10.1002/mrd.22430
|
[17]
|
Han, B., Li, K., Zhao, Y., et al. (2018) Anlotinib as a Third-Line Therapy in Patients with Refractory Advanced Non-Small-Cell Lung Cancer: A Multicentre, Randomised Phase II Trial (ALTER0302). British Journal of Cancer, 118, 654-661. https://doi.org/10.1038/bjc.2017.478
|
[18]
|
Cheng, Y., Han, B., Li, K., et al. (2020) Effect of Anlotinib as a Third or Further-Line Therapy in Advanced Non-Small Cell Lung Cancer Patients with Different Histologic Types: Subgroup Analysis in the ALTER0303 Trial. Cancer Medicine, 9, 2621-2630. https://doi.org/10.1002/cam4.2913
|
[19]
|
Liang, W., Zhao, Y., Zhang, Y., et al. (2018) The Impact of Anlotinib on Brain Metastases of NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303). Journal of Thoracic Oncology, 13, S665.
https://doi.org/10.1016/j.jtho.2018.08.1055
|
[20]
|
Chu, T., Zhang, W., Zhang, B., et al. (2022) Efficacy and Safety of First-Line Anlotinib-Based Combinations for Advanced Non-Small Cell Lung Cancer: A Three-Armed Prospective Study. Translational Lung Cancer Research, 11, 1394. https://doi.org/10.21037/tlcr-22-438
|
[21]
|
Yang, X., et al. (2019) Anlotinib Combined with S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Pro-tocol for Phase II Clinical Trial. Asian Pacific Journal of Cancer Prevention: APJCP, 20, 3849-3853.
https://doi.org/10.31557/APJCP.2019.20.12.3849
|
[22]
|
Huang, D., Zhong, D., Zhang, C., et al. (2020) Study of Anlotinib Combined with Icotinib as the First-Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients Har-boring Activating EGFR Mutations (ALTER-L004). Journal of Clinical Oncology, 38, 9573. https://doi.org/10.1200/JCO.2020.38.15_suppl.9573
|
[23]
|
Shi, Y., Ji, M., Jiang, Y., et al. (2022) A Cohort Study of the Efficacy and Safety of Immune Checkpoint Inhibitors plus Anlotinib versus Immune Checkpoint Inhibitors Alone as the Treatment of Advanced Non-Small Cell Lung Cancer in the Real World. Translational Lung Cancer Research, 11, 1051-1068. https://doi.org/10.21037/tlcr-22-350
|
[24]
|
Xiang, Y., Lu, X.J., Sun, Y.H., et al. (2022) Precise Thera-peutic Benefits and Underlying Mechanisms of Anlotinib Combined with Checkpoint Immunotherapy in Advanced Non-Small-Cell Lung Cancer. World Journal of Oncology, 13, 320-324. https://doi.org/10.14740/wjon1494
|
[25]
|
Sun, Y., Niu, W., Du, F., et al. (2016) Safety, Pharmacokinetics, and An-titumor Properties of Anlotinib, an Oral Multi-Target Tyrosine Kinase Inhibitor, in Patients with Advanced Refractory Solid Tumors. Journal of Hematology & Oncology, 9, 105. https://doi.org/10.1186/s13045-016-0332-8
|
[26]
|
Dobbin, S., Cameron, A.C., Petrie, M.C., et al. (2018) Toxicity of Cancer Therapy: What the Cardiologist Needs to Know about Angiogenesis Inhibitors. Heart (British Cardiac Society), 104, 1995-2002.
https://doi.org/10.1136/heartjnl-2018-313726
|
[27]
|
Touyz, R.M., Lang, N.N., Herrmann, J., et al. (2017) Recent Advances in Hypertension and Cardiovascular Toxicities with Vascular Endothelial Growth Factor Inhibition. Hyperten-sion, 70, 220-226.
https://doi.org/10.1161/HYPERTENSIONAHA.117.08856
|
[28]
|
Si, X., Zhang, L., Wang, H., et al. (2019) Man-agement of Anlotinib-Related Adverse Events in Patients with Advanced Non-Small Cell Lung Cancer: Experiences in ALTER-0303: Adverse Event Management of Anlotinib. Thoracic Cancer, 10, 551-556. https://doi.org/10.1111/1759-7714.12977
|
[29]
|
Lr, A., Rd, B., Tp, A., et al. (2019) Management of Adverse Events Associated with Tyrosine Kinase Inhibitors: Improvingoutcomes for Patients with Hepatocellular Carcinoma. Cancer Treatment Reviews, 77, 20-28.
https://doi.org/10.1016/j.ctrv.2019.05.004
|
[30]
|
Miura, S.I., Fujino, M., Matsuo, Y., et al. (2005) Nifedi-pine-Induced Vascular Endothelial Growth Factor Secretion from Coronary Smooth Muscle Cells Promotes Endothelial Tube Formation via the Kinase Insert Domain-Containing Receptor/Fetal Liver Kinase-1/NO Pathway. Hypertension Re-search, 28, 147-153.
https://doi.org/10.1291/hypres.28.147
|
[31]
|
Sastre, J., Argilés, G., Benavides, M., et al. (2014) Clinical Manage-ment of Regorafenib in the Treatment of Patients with Advanced Colorectal Cancer. Clinical & Translational Oncology, 16, 942-953.
https://doi.org/10.1007/s12094-014-1212-8
|
[32]
|
Mitchell, J., Khoukaz, T., Mcneal, D., et al. (2014) Adverse Event Management Strategies: Optimizing Treatment with Regorafenib in Patients with Metastatic Colorectal Cancer. Clinical Journal of Oncology Nursing, 18, E19-E25.
https://doi.org/10.1188/14.CJON.E19-E25
|
[33]
|
Srinivas, S., Stein, D., Teltsch, D.Y., et al. (2017) Real-World Chart Review Study of Adverse Events Management in Patients Taking Tyrosine Kinase Inhibitors to Treat Metastatic Renal Cell Carcinoma. Journal of Oncology Pharmacy Practice, 24, 574-583. https://doi.org/10.1177/1078155217719583
|
[34]
|
Berger, A.M., Mooney, K., Alvarez-Perez, A., et al. (2015) Can-cer-Related Fatigue, Version 2. Journal of the National Comprehensive Cancer Network, 13, 1012-1039. https://doi.org/10.6004/jnccn.2015.0122
|
[35]
|
Bower, J.E., Ba, K.K., Berger, A., et al. (2014) Screening, Assess-ment, and Management of Fatigue in Adult Survivors of Cancer: An American Society of Clinical Oncology Clinical Practice Guideline Adaptation. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncol-ogy, 32, 1840-1850.
https://doi.org/10.1200/JCO.2013.53.4495
|
[36]
|
Kim, S.Y., Kim, S.M., Chang, H., et al. (2019) Safety of Tyrosine Kinase Inhibitors in Patients with Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea. Frontiers in Endocrinology, 10, 384.
https://doi.org/10.3389/fendo.2019.00384
|
[37]
|
Ding, F.X., et al. (2019) Risk of Hand-Foot Skin Reaction Associ-ated with VEGFR-TKIs: A Meta-Analysis of 57 Randomized Controlled Trials Involving 24,956 Patients. Journal of the American Academy of Dermatology, 83, 788-796. https://doi.org/10.1016/j.jaad.2019.04.021
|
[38]
|
Li, J. and Gu, J. (2017) Hand-Foot Skin Reaction with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Can-cer Patients: A Systematic Review and Meta-Analysis. Critical Reviews in Oncology/Hematology, 119, 50-58. https://doi.org/10.1016/j.critrevonc.2017.09.016
|
[39]
|
Schmidinger, M. (2013) Understanding and Managing Toxic-ities of Vascular Endothelial Growth Factor (VEGF) Inhibitors. EJC Supplements, 11, 172-191. https://doi.org/10.1016/j.ejcsup.2013.07.016
|
[40]
|
Wang, D., Lehman, R.E., Donner, D.B., et al. (2002) Expression and Endocytosis of VEGF and Its Receptors in Human Colonic Vascular Endothelial Cells. American Journal of Physi-ology Gastrointestinal & Liver Physiology, 282, G1088. https://doi.org/10.1152/ajpgi.00250.2001
|
[41]
|
Fan, L. and Iseki, S. (1998) Immunohistochemical Localization of Vascular Endothelial Growth Factor in the Endocrine Glands of the Rat. Archives of Histology & Cytology, 61, 17. https://doi.org/10.1679/aohc.61.17
|
[42]
|
Placidi, E., Marciani, L., Hoad, C.L., et al. (2012) The Effects of Loperamide, or Loperamide plus Simethicone, on the Distribution of Gut Water as Assessed by MRI in a Mannitol Model of Secretory Diarrhoea. Alimentary Pharmacology & Therapeutics, 36, 64-73. https://doi.org/10.1111/j.1365-2036.2012.05127.x
|
[43]
|
Abbas, A., Mirza, M.M., Ganti, A.K., et al. (2015) Renal Toxicities of Targeted Therapies. Targeted Oncology, 10, 487-499. https://doi.org/10.1007/s11523-015-0368-7
|
[44]
|
Estrada, C.C., Maldonado, A. and Mallipattu, S.K. (2019) Thera-peutic Inhibition of VEGF Signaling and Associated Nephrotoxicities. Journal of the American Society of Nephrology, 30, 187-200.
https://doi.org/10.1681/ASN.2018080853
|
[45]
|
Shao, F., Zhang, H., Yang, X., et al. (2020) Adverse Events and Management of Apatinib in Patients with Advanced or Metastatic Cancers: A Review. Neoplasma, 67, 715-723. https://doi.org/10.4149/neo_2020_190801N701
|